PET/MRI for Staging the Axilla in Breast Cancer: Current Evidence and the Rationale for SNB vs. PET/MRI Trials
Authors:
- Rosa Di MiccoRMRosa Di Micco
- Letizia SanturroLSLetizia Santurro
- Maria Luisa GasparriMaria Luisa Gasparri
- Veronica ZuberVZVeronica Zuber
- Giovanni CisterninoGCGiovanni Cisternino
- Sara BaleriSBSara Baleri
- Manuela MorganteMMManuela Morgante
- Nicole RotmenszNRNicole Rotmensz
- Carla CanevariCCCarla Canevari
- Francesca GallivanoneFGFrancesca Gallivanone
- Paola ScifoPSPaola Scifo
- Annarita SaviASAnnarita Savi
Open Access
Abstract
Axillary surgery in breast cancer (BC) is no longer a therapeutic procedure but has become a purely staging procedure. The progressive improvement in imaging techniques has paved the way to the hypothesis that prognostic information on nodal status deriving from surgery could be obtained with an accurate diagnostic exam. Positron emission tomography/magnetic resonance imaging (PET/MRI) is a relatively new imaging tool and its role in breast cancer patients is still under investigation. We reviewed the available literature on PET/MRI in BC patients. This overview showed that PET/MRI yields a high diagnostic performance for the primary tumor and distant lesions of liver, brain and bone. In particular, the results of PET/MRI in staging the axilla are promising. This provided the rationale for two prospective comparative trials between axillary surgery and PET/MRI that could lead to a further de-escalation of surgical treatment of BC. • SNB vs. PET/MRI 1 trial compares PET/MRI and axillary surgery in staging the axilla of BC patients undergoing primary systemic therapy (PST). • SNB vs. PET/MRI 2 trial compares PET/MRI and sentinel node biopsy (SNB) in staging the axilla of early BC patients who are candidates for upfront surgery. Finally, these ongoing studies will help clarify the role of PET/MRI in BC and establish whether it represents a useful diagnostic tool that could guide, or ideally replace, axillary surgery in the future.Keywords
Funding Information
- Associazione Italiana per la Ricerca sul Cancro (IG21840)
- Ministero della Salute (RF-2018-12368096)
This publication has 74 references indexed in Scilit:
- PET/CT versus body coil PET/MRI: how low can you go?Insights into Imaging, 2013
- Abandoning sentinel lymph node biopsy in early breast cancer? A new trial in progress at the European Institute of Oncology of Milan (SOUND: entinel node vs bservation after axillary ltraSou )The Breast, 2012
- Molecular Imaging in Breast Cancer: From Whole-Body PET/CT to Dedicated Breast PETJournal of Oncology, 2012
- First Clinical Experience with Integrated Whole-Body PET/MR: Comparison to PET/CT in Patients with Oncologic DiagnosesJournal of Nuclear Medicine, 2012
- Breast cancer: from “maximum tolerable” to “minimum effective” treatmentFrontiers in Oncology, 2012
- Performance Measurements of the Siemens mMR Integrated Whole-Body PET/MR ScannerJournal of Nuclear Medicine, 2011
- Preoperative Ultrasound-Guided Needle Biopsy of Axillary Nodes in Invasive Breast CancerAnnals of Surgery, 2011
- Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trialThe Lancet Oncology, 2010
- Sentinel Lymph Node Biopsy in Breast CancerAnnals of Surgery, 2010
- Twenty-Year Follow-up of a Randomized Study Comparing Breast-Conserving Surgery with Radical Mastectomy for Early Breast CancerNew England Journal of Medicine, 2002